NCT02118987View on ClinicalTrials.gov

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

PHASE1CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Drug Allergy

Interventions

DRUG

Omalizumab

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER